特利加压素在难治性感染性休克患者中的应用效果观察

Clinical effect of terlipressin in refractory septic shock

目的观察特利加压素在难治性感染性休克中的应用效果。方法选取本院2014年7月至2016年8月收治的80例难治性感染性休克患者，随机分为对照组及观察组各40例。两组患者均给予多巴胺及去甲肾上腺素治疗，观察组在此基础上加用特利加压素。观察两组患者MAP、SVRI、尿量、BUN、SCr、去甲肾上腺素等指标水平情况。结果治疗后，观察组MAP、SVRI、尿量、BUN、SCr及去甲肾上腺素指标水平分别为（79．91±6．74）mmHg、（2099．97±234．24）、（1．15±0．33）ml·kg^-1·h^-1、（8．59±2．01）mmol／L、（102．17±28．73）μmol／L、（0．04±0．01）μg·kg^-1·min^-1，均优于对照组，差异有统计学意义（P〈0．05）。结论对难治性感染性休克患者在常规治疗基础上加用特利加压素，对患者MAP、SVRI、尿量、BUN、SCr、去甲肾上腺素等指标水平影响好，临床应用效果好。

Objective To observe the clinical application effect of terlipressin in the treatment of refractory septic shock. Methods 80 patients with refractory septic shock treated in our hospital from July 2014 to August 2016 were selected and randomly divided into control group and observation group, 40 cases in each group. Both two groups were treated with dopamine and norepinephrine. On the basis, the observation group was treated with terlipressin. The indexes including MAP, SVRI, urine volume, BUN, SCr, and norepinephrine of two groups were observed. Results After treatment, the levels of MAP, SVRI, urine volume, BUN,SCr, and norepinephrine of observation group were （79.91±6.74）mmHg, （2 099.97±234.24）, （1.15±0.33）ml·kg^-1·h^-1, （8.59±2.01）mmol/L, （ 102.17±28.73）μmol/L, （0.04±0.01）μg·kg^-1·min^-1, significantly better than those of control group （P〈0.05）. Conclusion For patients with refractory septic shock, terlipressin on the basis of conventional therapy can improve the indexes of MAP, SVRI, urine volume, BUN, SCr, and norepinephrine in clinical practice.